Overcoming biological barriers BBB/BBTB by designing PUFA functionalised lipid-based nanocarriers for glioblastoma targeted therapy
Source abstract
Abstract
A major obstacle for chemotherapeutics in Glioblastoma (GB) is to reach the tumour cells due to the presence of the blood-brain barrier (BBB) and chemoresistance of anticancer drugs. The present study reports two polyunsaturated fatty acids, gamma-linolenic acid (GLA) and alpha-linolenic acid (ALA) appended nanostructured lipid carriers (NLCs) of a CNS negative chemotherapeutic drug docetaxel (DTX) for targeted delivery to GB. The ligand appended DTX-NLCs demonstrated particle size ˂160 nm, PDI˂0.29 and negative surface charge. The successful linkage of GLA (41 %) and ALA (30 %) ligand conjugation to DTX- NLCs was confirmed by diminished surface amino groups on the NLCs, lower surface charge and FTIR profiling. Fluorophore labelled GLA-DTX-NLCs and ALA-DTX-NLCs permeated the in-vitro 3D BBB with Papp values of 1.8 × 10−3 and 1.9 × 10−3 cm/s respectively Following permeation, both formulations showed enhanced uptake by GB immortalised cells while ALA-DTX-NLCs showed higher uptake in patient-derived GB cells as evidenced in an in-vitro 3D blood brain tumour barrier (BBTB) model. Both surface functionalised formulations showed higher internalisation in GB cells as compared to bare DTX-NLCs. ALA-DTX-NLCs and GLA-DTX-NLCs showed 13.9-fold and 6.8-fold higher DTX activity respectively at 24 h as indicated by IC50 values when tested in patient-derived GB cells. ALA-DTX-NLCs displayed better efficacy than GLA-DTX-NLCs when tested against 3D tumour spheroids and patient-derived cells. These novel formulations will contribute widely to overcoming biological barriers for treating glioblastoma.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (71)
Show source-provided references
1. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma10.1016/j.lfs.2011.04.022 ↗
2. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles10.1016/j.biomaterials.2012.07.046 ↗
3. Nanoparticles for brain drug delivery10.1155/2013/238428 ↗
4. Taxanes: promising anti-cancer drugs
5. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases10.1016/j.pneurobio.2005.04.006 ↗
6. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment10.1080/10717544.2019.1616235 ↗
7. Materials Science & Engineering C Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB / BBTB models
8. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations10.1016/S0169-409X(02)00118-7 ↗
9. Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours. Futur
10. Michalak · 2016 · vol. 7
11. Highly unsaturated fatty acid induced tumour regression in glioma pharmacodynamics and bioavailability of gamma linolenic acid in an implantation glioma model: effects on tumour biomass, apoptosis and neuronal tissue histology10.1054/plef.2002.0431 ↗
12. Essential fatty acids, lipid peroxidation and apoptosis10.1054/plef.1999.0085 ↗
13. Effects of N-6 essential fatty acids on glioma invasion and growth: experimental studies with glioma spheroids in collagen gels10.3171/jns.1999.91.6.0989 ↗
14. Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression10.1186/1476-511X-8-8 ↗
15. Comparative toxicity of oleic acid and linoleic acid on Raji cells10.1016/j.nut.2004.07.007 ↗
16. Eicosapentaenoic acid induces fas-mediated apoptosis through a p53-dependent pathway in hepatoma cells10.1097/00130404-200405000-00009 ↗
17. γ-Linolenic acid therapy of human glioma - a review of in vitro, in vivo, and clinical studies
18. Anticancer activities of fatty acids and their heterocyclic derivatives10.1016/j.ejphar.2020.172937 ↗
19. Conjugation with α-linolenic acid improves cancer cell uptake and cytotoxicity of doxorubicin10.1016/j.bmcl.2009.03.016 ↗
20. Comparison of stearidonic acid and α-linolenic acid on PGE 2 production and COX-2 protein levels in MDA-MB-231 breast cancer cell cultures10.1016/j.jnutbio.2004.11.001 ↗
21. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ10.1073/pnas.94.9.4312 ↗
22. B-FABP-expressing radial glial cells: the malignant glioma cell of origin?10.1593/neo.07439 ↗
23. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme10.1073/pnas.0402870102 ↗
24. Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization10.3389/fmolb.2020.587012 ↗
25. Fatty acid transport protein expression in human brain and potential role in fatty acid transport across human brain microvessel endothelial cells
26. Transferrin-modified chitosan nanoparticles for targeted nose-to-brain delivery of proteins10.1007/s13346-022-01245-z ↗
27. Optimization of preparation and property studies on glycosylated albumin as drug carrier for nanoparticles
28. A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells10.1016/j.jconrel.2016.07.032 ↗
29. P50 * developing a physiologically relevant blood brain barrier model for the study of drug disposition in glioma
30. Docetaxel loaded PEG-PLGA nanoparticles: optimized drug loading, in-vitro cytotoxicity and in-vivo antitumor effect
31. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma10.1016/j.biomaterials.2008.09.014 ↗
32. P-Aminophenyl-α-d-mannopyranoside engineered lipidic nanoparticles for effective delivery of docetaxel to brain10.1016/j.chemphyslip.2015.03.003 ↗
33. Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy10.1016/j.actbio.2013.06.034 ↗
34. Impact of liquid lipid on development and stability of trimyristin nanostructured lipid carriers for oral delivery of resveratrol
35. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy10.1021/acsnano.6b04268 ↗
36. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability10.1023/A:1016212804288 ↗
37. From bench to the clinic: -linolenic acid therapy of human gliomas10.1016/j.plefa.2003.12.001 ↗
38. Nontransformed and cancer cells can utilize different endocytic pathways to internalize dendritic nanoparticle variants: implications on nanocarrier design10.1021/acs.biomac.7b00590 ↗
39. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells10.1016/S0959-8049(00)00408-1 ↗
40. Study of efficiency of coupling peptides with gold nanoparticles10.1016/S1872-2040(17)61013-2 ↗
41. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin
42. Effect of ligand density, receptor density, and nanoparticle size on cell targeting
43. Crossing the blood-brain barrier with nanoparticles10.1016/j.jconrel.2017.12.015 ↗
44. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles10.1517/17425247.2013.784742 ↗
45. Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth10.1039/C4TB01442A ↗
46. Size, shape, and flexibility influence nanoparticle transport across brain endothelium under flow10.1002/btm2.10153 ↗
47. Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity10.1080/08982104.2019.1614055 ↗
48. Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells10.1080/08982104.2017.1370471 ↗
49. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel10.1016/j.colsurfb.2011.02.038 ↗
50. Endothelial tight junctions: permeable barriers of the vessel wall
51. Singh
52. Mechanism of mucosal permeability enhancement of CriticalSorb® (Solutol® HS15) investigated in vitro in cell cultures10.1007/s11095-014-1481-5 ↗
53. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance
54. Multivariate optimization of rizatriptan benzoate-loaded solid lipid nanoparticles for brain targeting and migraine management10.1208/s12249-016-0532-0 ↗
55. Solid lipid nanoparticles for targeted brain drug delivery☆10.1016/j.addr.2007.04.011 ↗
56. Isolation and expression of a cDNA for human brain fatty acid-binding protein (B-FABP)10.1016/S0167-4781(97)00115-2 ↗
57. Interaction of brain fatty acid-binding protein with the polyunsaturated fatty acid environment as a potential determinant of poor prognosis in malignant glioma10.1016/j.plipres.2013.08.004 ↗
58. Regulation of brain polyunsaturated fatty acid uptake and turnover
59. Antitumour and pro-apoptotic actions of highly unsaturated fatty acids in glioma
60. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells
61. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases10.1016/j.nbd.2009.07.028 ↗
62. Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model10.1007/s11060-012-1006-1 ↗
63. Glioblastoma cell-secreted Interleukin-8 induces brain endothelial cell permeability via CXCR2
64. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway
65. γ-Linolenic acid therapy of human gliomas10.1016/S0899-9007(02)00862-6 ↗
66. In vitro and in vivo intracellular distribution and anti-glioblastoma effects of docetaxel-loaded nanoparticles functioned with IL-13 peptide
67. Penetration and uptake of nanoparticles in 3D tumor spheroids10.1021/acs.bioconjchem.9b00136 ↗
68. Induction of cell death by doxorubicin in multicellular spheroids as studied by confocal laser scanning microscopy
69. Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment10.1016/j.biomaterials.2013.11.076 ↗
70. DNA damage responses in cell cycle G2 phase and mitosis - tracking and targeting
71. Nanotechnology inspired tools for mitochondrial dysfunction related diseases10.1016/j.addr.2015.12.024 ↗